Twist Bioscience Co. (NASDAQ:TWST) Insider Dennis Cho Sells 277 Shares

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) insider Dennis Cho sold 277 shares of the business's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total transaction of $11,332.07. Following the completion of the transaction, the insider now directly owns 111,984 shares in the company, valued at $4,581,265.44. This trade represents a 0.25 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Dennis Cho also recently made the following trade(s):

• On Monday, February 3rd, Dennis Cho sold 806 shares of Twist Bioscience stock. The shares were sold at an average price of $49.35, for a total transaction of $39,776.10.
• On Friday, January 3rd, Dennis Cho sold 144 shares of Twist Bioscience stock. The shares were sold at an average price of $45.59, for a total transaction of $6,564.96.
• On Friday, December 20th, Dennis Cho sold 316 shares of Twist Bioscience stock. The stock was sold at an average price of $44.90, for a total value of $14,188.40.
• On Monday, December 16th, Dennis Cho sold 133 shares of Twist Bioscience stock. The shares were sold at an average price of $46.81, for a total value of $6,225.73.

Twist Bioscience Trading Up 1.7 %

TWST stock traded up $0.65 during trading on Friday, hitting $39.77. The company had a trading volume of 396,260 shares, compared to its average volume of 992,561. Twist Bioscience Co. has a 52-week low of $27.41 and a 52-week high of $60.90. The company has a 50 day simple moving average of $45.91 and a 200-day simple moving average of $45.31. The firm has a market capitalization of $2.37 billion, a P/E ratio of -11.77 and a beta of 2.15. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Remove Ads

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. During the same quarter in the previous year, the firm posted ($0.75) earnings per share. The company's revenue was up 24.1% on a year-over-year basis. As a group, research analysts forecast that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

TWST has been the topic of several recent research reports. Scotiabank reaffirmed an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. TD Cowen reiterated a "buy" rating and set a $58.00 price objective on shares of Twist Bioscience in a research report on Tuesday, November 26th. Wolfe Research assumed coverage on Twist Bioscience in a research report on Friday, December 13th. They set an "outperform" rating and a $60.00 target price on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research report on Tuesday, February 4th. Finally, Robert W. Baird raised their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $54.40.

Institutional Investors Weigh In On Twist Bioscience

Several hedge funds have recently made changes to their positions in TWST. Massachusetts Financial Services Co. MA lifted its stake in Twist Bioscience by 215.9% in the third quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company's stock worth $1,324,000 after acquiring an additional 20,035 shares during the period. Barclays PLC raised its holdings in shares of Twist Bioscience by 214.8% in the 3rd quarter. Barclays PLC now owns 153,039 shares of the company's stock valued at $6,913,000 after purchasing an additional 104,420 shares in the last quarter. FMR LLC lifted its position in shares of Twist Bioscience by 6.0% in the 3rd quarter. FMR LLC now owns 218,561 shares of the company's stock worth $9,875,000 after purchasing an additional 12,327 shares during the period. Avanza Fonder AB bought a new position in shares of Twist Bioscience during the fourth quarter valued at approximately $1,059,000. Finally, BNP Paribas Financial Markets increased its holdings in Twist Bioscience by 128.1% during the third quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company's stock valued at $1,718,000 after buying an additional 21,357 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.